SCHEMBL6707928

SCHEMBL6707928

Cc1noc(-c2ccccc2Cl)c1C(=O)Nc1ccccn1

nearest known ligand 0.66

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.66
ALOX15 P16050 1/20 0.66
L3MBTL1 Q9Y468 1/20 0.66
SMN1; SMN2 Q16637 5/20 0.54
RAB9A P51151 5/20 0.54
NPC1 O15118 4/20 0.54
TDP1 Q9NUW8 1/20 0.52
EPAS1 Q99814 1/20 0.49
LMNA P02545 4/20 0.48
THRB P10828 1/20 0.48
GPBAR1 Q8TDU6 1/20 0.47
TSHR P16473 2/20 0.46
HTT P42858 2/20 0.46
MAPT P10636 1/20 0.46
RIPK1 Q13546 1/20 0.46
CYP1A2 P05177 1/20 0.45
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
GRM5 P41594 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29059230 0.83 EPAS1 (0.73) ALDH1A1ALOX15L3MBTL1SMN1; SMN2RAB9A
SCHEMBL6707303 0.82 ALDH1A1 (0.46) ALDH1A1ALOX15L3MBTL1SMN1; SMN2RAB9A
SCHEMBL6710865 0.80 ALDH1A1 (1.00) ALDH1A1ALOX15L3MBTL1SMN1; SMN2RAB9A
SCHEMBL30395754 0.77 KMT2A (0.49) ALDH1A1L3MBTL1NPC1LMNATHRB
SCHEMBL12543516 0.77 KMT2A (0.49) ALDH1A1L3MBTL1NPC1LMNATHRB
SCHEMBL11517536 0.77 HSD17B10 (0.52) ALDH1A1L3MBTL1NPC1EPAS1LMNA
SCHEMBL6710711 0.77 ALDH1A1 (0.50) ALDH1A1ALOX15L3MBTL1SMN1; SMN2RAB9A
SCHEMBL6709091 0.76 EPAS1 (0.56) ALDH1A1SMN1; SMN2RAB9ANPC1TDP1
SCHEMBL30576270 0.76 HSD17B10 (0.62) ALDH1A1EPAS1LMNATHRBGPBAR1
SCHEMBL6709187 0.74 NPC1 (0.66) ALDH1A1SMN1; SMN2RAB9ANPC1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040102489-A1 Heteroarylcarboxamide compounds active against protein tyrosine kinase related disorders SUGEN, INC. 2004-05-27 US disclosed
US-6649635-B2 For therapy of cancer SUGEN, INC. 2003-11-18 US disclosed
US-20020065283-A1 Heteroarylcarboxamide compounds active against protein tyrosine kinase related disorders MCMAHON GERALD (US) 2002-05-30 US disclosed
EP-1012150-A4 HETEROARYLCARBOXAMIDE COMPOUNDS ACTIVE AGAINST PROTEIN TYROSINE KINASE RELATED DISORDERS SUGEN INC (US) 2002-05-29 EP disclosed
US-6316479-B1 ANTICANCER AGENTS SUGEN, INC. 2001-11-13 US disclosed
EP-1012150-A1 HETEROARYLCARBOXAMIDE COMPOUNDS ACTIVE AGAINST PROTEIN TYROSINE KINASE RELATED DISORDERS Sugen, Inc. (US) 2000-06-28 EP disclosed
WO-1998052944-A1 HETEROARYLCARBOXAMIDE COMPOUNDS ACTIVE AGAINST PROTEIN TYROSINE KINASE RELATED DISORDERS SUGEN, INC. (US) 1998-11-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020065283-A1 Heteroarylcarboxamide compounds active against protein tyrosine kinase related disorders ABL1, ERBB2, PRKDC ALDH1A1 3956/4885ALOX15 4365/4885L3MBTL1 1271/4885
US-20040102489-A1 Heteroarylcarboxamide compounds active against protein tyrosine kinase related disorders ABL1, ERBB2, PRKDC ALDH1A1 3956/4885ALOX15 4365/4885L3MBTL1 1271/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.